Vericel (VCEL) Reaches New 52-Week High at $17.90

Shares of Vericel Corp (NASDAQ:VCEL) hit a new 52-week high during trading on Monday . The company traded as high as $17.90 and last traded at $17.48, with a volume of 25520 shares trading hands. The stock had previously closed at $16.84.

VCEL has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating and set a $17.00 price target on shares of Vericel in a research note on Tuesday, August 7th. Needham & Company LLC dropped their price target on shares of Vericel from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, August 8th. Finally, BidaskClub cut shares of Vericel from a “hold” rating to a “sell” rating in a research note on Tuesday, October 23rd. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Vericel presently has a consensus rating of “Buy” and a consensus target price of $16.75.

The company has a market cap of $729.97 million, a P/E ratio of -35.76 and a beta of 3.36. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.71 and a current ratio of 7.96.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.02) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.09. Vericel had a negative net margin of 15.80% and a negative return on equity of 17.39%. The company had revenue of $22.50 million for the quarter, compared to analysts’ expectations of $18.14 million. The firm’s revenue was up 57.3% compared to the same quarter last year. On average, analysts forecast that Vericel Corp will post -0.23 EPS for the current year.

In other Vericel news, Director Steven C. Gilman sold 9,000 shares of the stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $12.03, for a total value of $108,270.00. Following the sale, the director now directly owns 9,000 shares in the company, valued at approximately $108,270. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gerard J. Michel sold 15,000 shares of the stock in a transaction that occurred on Monday, November 12th. The stock was sold at an average price of $15.90, for a total transaction of $238,500.00. The disclosure for this sale can be found here. Insiders sold a total of 179,000 shares of company stock worth $2,617,770 over the last quarter. Corporate insiders own 4.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of VCEL. BlackRock Inc. lifted its stake in Vericel by 145.5% in the 2nd quarter. BlackRock Inc. now owns 2,586,435 shares of the biotechnology company’s stock worth $25,089,000 after purchasing an additional 1,532,840 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Vericel in the 2nd quarter worth approximately $5,196,000. Mutual of America Capital Management LLC purchased a new stake in Vericel in the 2nd quarter worth approximately $3,917,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Vericel during the 2nd quarter valued at $3,880,000. Finally, Teachers Advisors LLC raised its position in shares of Vericel by 531.8% during the 3rd quarter. Teachers Advisors LLC now owns 446,296 shares of the biotechnology company’s stock valued at $6,315,000 after buying an additional 375,654 shares in the last quarter. Institutional investors and hedge funds own 76.56% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by WKRB News and is the property of of WKRB News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at

Vericel Company Profile (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

Featured Story: Growth Stocks

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with's FREE daily email newsletter.

Leave a Reply